QPPV.COM KNOWLEDGE ASSESSMENT

EMA Referral Procedures: Professional Knowledge Assessment

Test your understanding of the concepts covered by What Is an EMA Referral? Why Referrals Are Started and How the EU Referral System Works.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the principal risk of treating every product named in a referral as if all aspects of its authorisation were being reassessed?

Under-reporting adverse events Over-scoping the scientific and operational response beyond the referred questions Preventing PRAC from reviewing the safety issue Automatically converting a national authorisation into a central authorisation

Question 2 of 10 What should primarily determine the choice between Article 20, Article 30, Article 31 and Article 107i?

The seriousness of the adverse event alone The committee that is most familiar with the product The legal trigger and statutory conditions applicable to the situation The number of Member States in which the product is marketed

Question 3 of 10 Which sequence most accurately separates scientific assessment from legal implementation?

Evidence, scientific assessment, benefit-risk conclusion, recommendation or opinion, legal decision, implementation Public summary, recall, signal validation, committee appointment, implementation Legal decision, evidence generation, referral notification, scientific assessment, implementation MAH preference, committee minutes, product launch, legal decision, monitoring

Question 4 of 10 A pharmacovigilance team validates a possible new adverse reaction. Which interpretation is most appropriate at this stage?

A formal Article 31 referral has necessarily begun The product must immediately be recalled The information is a safety signal requiring further evaluation, but it is not necessarily a referral The issue can only be handled through Article 107i

Question 5 of 10 Which statement best distinguishes PRAC, CHMP and CMDh in the referral system?

PRAC coordinates national authorisations, CHMP handles only manufacturing, and CMDh assesses all safety signals PRAC has defined pharmacovigilance assessment responsibilities, CHMP is a principal human-medicines scientific committee, and CMDh coordinates positions for nationally authorised medicines in relevant contexts All three committees perform the same function and are interchangeable CMDh adopts every final Commission decision

Question 6 of 10 When should an MAH consider a referral operationally closed?

When the referral first appears on the EMA website When the rapporteur's preliminary assessment is available When all applicable regulatory, product-information, pharmacovigilance, quality, communication and commitment activities are completed and documented When the MAH submits its initial response

Question 7 of 10 Which document should be the primary starting point for determining the products and regulatory questions within a referral's scope?

A general EMA webpage about referrals The company's most recent periodic safety report The formal referral notification and procedure-specific documents A committee meeting highlight

Question 8 of 10 Which statement best reflects the relationship between an identified safety risk and withdrawal of a marketing authorisation?

Any identified risk requires withdrawal A referral itself is evidence that withdrawal has occurred Withdrawal is one possible outcome, but the decision depends on integrated benefit-risk assessment and the final legal instrument Withdrawal is never permitted after a referral

Question 9 of 10 For a nationally authorised medicine, what should an implementation plan assess after a Union-level referral outcome?

Only the EMA webpage publication date Affected national authorisations, required submissions, competent-authority actions, deadlines and effective dates Only the product's global commercial launch status Whether the product should automatically become centrally authorised

Question 10 of 10 What characteristic most clearly distinguishes an Article 107i procedure from a routine safety referral?

It concerns only centrally authorised medicines It is initiated by a marketing authorisation holder Urgent Union-level action is considered necessary because of a safety issue It is limited to product-information wording

EMA Referral Procedures: Professional Knowledge Assessment

Cookie Settings